

TEXCELL

Main Areas of Business




Cell culture

FR, USA



Immunoprofiling

FR, DE



Virology and BioSafety

FR, USA, TW



Biodistribution

DE




Biosafety
testing



Immuno-
profiling



Cell
Culture



Viral
Clearance



Biodistri-
bution

Texcell



Medical devices



Viral clearance




GMP Cell Banking




Biosafety



BioAssays in vivo



Research Cell Bank



BioAssays in vitro



Toxicology

2005

TEXCELL SA

Lab Extension



2010

TEXCELL North America

Acquisition of Frederick, Md



2015

TEXCELL ASIA

Taipei, Taiwan



2016

VIVO SCIENCE

Gronau, Germany



2017

TEXCELL JAPAN

Osaka




More than

10,000

virus clearance
tests



STEPS OF A “VIRUS CLEARANCE” TEST

Viral risk | 3 securisation steps



TWO nanoe™ X TESTS ON SARS-COV-2


45L BOX





6.7m³
WORKING
HOUSE

nanoe™ X TESTS ON SARS-COV-2

45L Box – comparison test for natural reduction & with nanoe™ X




**With
nanoe X**



PANASONIC ETHEREA TEST ON SARS-COV-2

6.7m³ working house




With
nanoe X




PANASONIC ETHEREA TEST ON SARS-COV-2

6.7m³ working house – The inhibiting effect

Etherea model
CS-Z25VKEW



Survival rate
100%



**With
nanoe X**